非小细胞肺癌的生物标志物：从实验室到临床
Biomarkers for Non-Small Cell Lung Cancer: From the Bench to the Bedside.
作者信息
de Mello Ramon Andrade, Amaral Giovanna Araújo
机构信息
Algarve Biomedical Centre, Department of Biomedical Sciences and Medicine University of Algarve (DCBM UALG), 8005-139 Faro, Portugal.
Division of Medical Oncology, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), São Paulo 04037-004, Brazil.
出版信息
J Clin Med. 2020 Oct 21;9(10):3376. doi: 10.3390/jcm9103376.
Abstract
Lung cancer (LC) is inarguably one of the biggest battles to be fought in the field of oncology, and non-small cell lung cancer accounts for over 85% of all lung cancer cases [...].
摘要
肺癌无疑是肿瘤学领域面临的最艰巨挑战之一，其中非小细胞肺癌占所有肺癌病例的85%以上[...]。
相似文献
1
Biomarkers for Non-Small Cell Lung Cancer: From the Bench to the Bedside.非小细胞肺癌的生物标志物：从实验室到临床
J Clin Med. 2020 Oct 21;9(10):3376. doi: 10.3390/jcm9103376.
2
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
3
Clinical potential of gene mutations in lung cancer.肺癌基因突变的临床潜力
Clin Transl Med. 2015 Dec;4(1):33. doi: 10.1186/s40169-015-0074-1. Epub 2015 Nov 24.
4
Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.癌症分子成像生物标志物的最新进展：从实验室到临床的技术应用。
Drug Discov Today. 2010 Feb;15(3-4):102-14. doi: 10.1016/j.drudis.2009.12.003. Epub 2009 Dec 24.
5
Non-coding RNA as lung disease biomarkers.非编码 RNA 作为肺部疾病的生物标志物。
Thorax. 2015 May;70(5):501-3. doi: 10.1136/thoraxjnl-2014-206193. Epub 2014 Dec 30.
6
Interventional bronchoscopy from bench to bedside: new techniques for early lung cancer detection.介入性支气管镜检查从实验室到临床：早期肺癌检测的新技术。
Clin Chest Med. 2010 Mar;31(1):29-37, Table of Contents. doi: 10.1016/j.ccm.2009.09.001.
7
From bedside to bench and back: Translating ASD models.从床边到实验台再回归床边：转化孤独症谱系障碍模型
Prog Brain Res. 2018;241:113-158. doi: 10.1016/bs.pbr.2018.10.003. Epub 2018 Nov 7.
8
From Bench to Bedside: Alpha-defensing--The Biggest Thing in Joint Replacement Infections Since Prophylactic Antibiotics?从实验室到临床：α-防御素——自预防性抗生素以来关节置换感染领域最重大的发现？
Clin Orthop Relat Res. 2015 Oct;473(10):3105-7. doi: 10.1007/s11999-015-4297-7. Epub 2015 Apr 14.
9
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.色瑞替尼在ROS1重排非小细胞肺癌中的临床活性：从 bench 到床边报告
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1419-20. doi: 10.1073/pnas.1522052113. Epub 2016 Feb 25.
10
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.泌尿肿瘤新药研发的窗口。第二部分：从 bench 到 bedside 的研究提高了泌尿生殖系统癌症的生存率，更好生物标志物的发现有助于预测患者的反应、毒性及对治疗的耐药性。
Urol Oncol. 2015 Jun;33(6):269. doi: 10.1016/j.urolonc.2015.01.026. Epub 2015 Mar 26.
引用本文的文献
1
Evaluating the User-Perceived Benefit of a Virtual Lung Cancer Patient Education and Support Community: LVNG With Lung Cancer.评估虚拟肺癌患者教育与支持社区（LVNG With Lung Cancer）的用户感知效益。
J Adv Pract Oncol. 2024 Jul 21:1-17. doi: 10.6004/jadpro.2024.15.8.8.
2
Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.晚期无驱动基因突变非小细胞肺癌患者的免疫治疗及未来展望
Cancers (Basel). 2021 Dec 28;14(1):122. doi: 10.3390/cancers14010122.
3
Exploration of Chemopreventive Potential of Linalool in Targeting Lung Cancer Biomarkers.探讨芳樟醇抑制肺癌生物标志物的化学预防潜力。
Endocr Metab Immune Disord Drug Targets. 2022;22(14):1416-1424. doi: 10.2174/1871530321666210909165426.
本文引用的文献
1
Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015.肺癌的经济负担：韩国 2002-2015 年的回顾性队列研究。
PLoS One. 2019 Feb 22;14(2):e0212878. doi: 10.1371/journal.pone.0212878. eCollection 2019.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.非小细胞肺癌治疗的（变）革：十年进展及未来展望
Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017.
4
Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer.肺癌患者的情绪问题、生活质量和症状负担
Clin Lung Cancer. 2017 Sep;18(5):497-503. doi: 10.1016/j.cllc.2017.02.008. Epub 2017 Mar 2.
5
Quality of life of patients with lung cancer.肺癌患者的生活质量。
Onco Targets Ther. 2016 Feb 29;9:1023-8. doi: 10.2147/OTT.S100685. eCollection 2016.
6
Economic burden of cancer in the United States: estimates, projections, and future research.美国癌症的经济负担：估计、预测和未来研究。
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14. doi: 10.1158/1055-9965.EPI-11-0650.
7
Personalized medicine in lung cancer: what we need to know.肺癌个体化医学：我们需要了解的内容。
Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8. doi: 10.1038/nrclinonc.2011.126.
8
The economic burden of lung cancer and the associated costs of treatment failure in the United States.美国肺癌的经济负担及治疗失败的相关成本。
Lung Cancer. 2005 Nov;50(2):143-54. doi: 10.1016/j.lungcan.2005.06.005. Epub 2005 Aug 19.
9
Evolution of non-small cell lung cancer chemotherapy (Review).非小细胞肺癌化疗的进展（综述）
Oncol Rep. 2005 May;13(5):923-30.
10
Lung cancer in US women: a contemporary epidemic.美国女性肺癌：一种当代流行病。
JAMA. 2004 Apr 14;291(14):1763-8. doi: 10.1001/jama.291.14.1763.
Zotero 插件